Shared insight on the combination of gemcitabine, cisplatin, and nivolumab in patients with muscle-invasive bladder cancer in the HCRN GU 16-257 trial.
The trial’s primary endpoint was achieved, establishing the maximum tolerated dose of SCO-101 in combination with the standard chemotherapies gemcitabine and nab-paclitaxel in patients with. | March 31, 2023
Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) time for patients with advanced biliary tract cancers, although it may provide a benefit for subsets of patients with locally advanced disease or gallbladder adenocarcinoma.